Levofloxacin: a therapeutic review (Q77899294)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

review article

1 reference

title

Levofloxacin: a therapeutic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

S M Wimer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

L Schoonover

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

M W Garrison

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

publication date

1 November 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

published in

Clinical Therapeutics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

1049-1070

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

Fluoroquinolone antimicrobial agents

9 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Mechanisms of quinolone resistance

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Mechanism of quinolone uptake into bacterial cells

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activity of levofloxacin, ofloxacin and other quinolones against coagulase-negative staphylococci.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Induction of resistance of Streptococcus pneumoniae to quinolones in vitro

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

The bactericidal activity of levofloxacin compared with ofloxacin, D- ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfioxacin, tosufloxacin, CI-960 and CI-990

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Comparative activities of eight quinolones against members of the Bacteroides fragilis group

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Enantioselective disposition of ofloxacin in humans

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

The clinical pharmacokinetics of levofloxacin

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Levofloxacin and Sparfloxacin: New Quinolone Antibiotics

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

The postantibiotic suppressive effect of L-ofloxacin, an optically active isomer of ofloxacin.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Multicenter, Randomized Study Comparing Levofloxacin and Ciprofloxacin for Uncomplicated Skin and Skin Structure Infections

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Overview of drug interactions with the quinolones

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Absence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered Levofloxacin

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Central nervous system toxicity of quinolones: human and animal findings

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Possible interaction of ciprofloxacin with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Levofloxacin does not alter cyclosporine disposition

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activity of sparfloxacin

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistantStaphylococcus aureus andStaphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activity of the new fluoroquinolone CP-99,219.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In-vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers' diarrhoea

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(98)80104-5

7 January 2021

10.1016/S0149-2918(98)80104-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9916602 AND SRC:MED&resulttype=core&format=json

9 December 2019

1 reference